NCT00637832 2022-01-06
Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma
University of Southampton
Phase 2 Terminated
University of Southampton
Merck Sharp & Dohme LLC
Seagen Inc.
Pfizer
UNC Lineberger Comprehensive Cancer Center
European Organisation for Research and Treatment of Cancer - EORTC